Author:
van Schaik B. A. M.,Geyskes G. G.,Boer P.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine
Reference21 articles.
1. Brunner DB, Desponds G, Biollaz J, Keller I, Ferber F, Gavras H, Brunner HR, Schelling JL (1981) Effect of a new angiotensin converting enzyme inhibition MK 421 and its lysine analogue on the components of the renin system in healthy subjects. Br J Clin Pharmacol 11: 461?467
2. Gavras H, Biollaz J, Waeber B, Brunner HR, Gavras I, Davies RO (1981) Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor MK-421. Lancet 2: 543?547
3. Sweet CS, Gross DM, Arbegast PI, Gaul SL, Britt PM, Ludden CT, Weits D, Stone CA (1981) Antihypertensive activity of N-[(s)-1-(ethoxycarbonyl)-3-phenyl-propyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor. J Pharmacol Exp Ther 216: 558?566
4. Ulm EH, Hichens M, Gomez HJ, Till EA, Hand EL, Vassil TC, Biollaz J, Brunner HR, Schelling JL (1982) Enalapril maleate and a lysine analogue (MK-521): Disposition in man. Br J Clin Pharmacol 14: 357?362
5. Millar JA, Derkx FHM, McLean K, Reid JL (1982) Pharmacodynamics of converting enzyme inhibition: The cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521. Br J Clin Pharmacol 14: 347?355
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献